Skip to main content
OpenTrials
Completed

NCT Number: NCT00487474

A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of SCULPTRA Measured by Three Dimensional Digital Surface Imaging

* Measure the mid-facial volumetric correction from SCULPTRA treatment, using three-dimensional digital surface imaging * Determine the mean change from baseline in facial contour deficiency as measured by the Dermik Nasolabial Photo-numeric Scale * Correlate volumetric correction with clinical improvement as measured by the Dermik Nasolabial Photo-numeric Scale * Correlate the mean volumetric change in mid-facial treatment area with the amount of product used * Evaluate subject and investigator global assessment of improvement and subject treatment satisfaction at the end of treatment * Obtain photographs pre- and post-treatment for the purpose of providing a subject visual aid during the course of treatment * Collect safety data

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

London, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must sign a statement of informed consent.
  • Subjects must be 18-75 years of age, of any race or gender.
  • Female patients of childbearing potential must have a negative urine pregnancy test prior to the first treatment with the product and must use an acceptable form of birth control throughout the study (e.g., oral/systemic contraceptives, an intrauterine device (IUD) or Norplant starting at least 28 days prior to study entry and throughout the study).
  • Subjects must display signs of facial contour deficiencies in the area of the nasolabial folds [nasolabial fold scores greater than or equal to 2 (bilaterally) on the Dermik Nasolabial Photo-numeric Scale.
  • Subjects must be a suitable candidate for SCULPTRA treatment.
  • Subjects must be able to understand the requirements of the study and be willing to comply with the study requirements

Exclusion criteria

  • Subjects with an allergy to any of the constituents of the product.
  • Subjects with a known history of keloids or bleeding disorders.
  • Subjects of childbearing potential who are pregnant, or plan to become pregnant within the study timeframe, or who are nursing.
  • Subjects with significant facial hair (e.g. mustaches, beards, etc.)
  • Subjects with an active inflammatory process or infection in the area to be treated (skin eruptions such as cysts, pimples, rashes, cancerous/pre-cancerous lesions, or any other active skin disease in the treatment area).
  • Subjects who plan to undergo major facial surgery [e.g., rhinoplasty (with or without implant), facelift, congenital defect repair, etc.] during the course of the study.
  • Subjects who have used or plan to use exclusionary medications/treatments.

Treatment and study plan

DL6049 (injectable poly-L-lactic acid)

Device

Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert

Other names: Sculptra

Primary outcomes

  1. Measure the mid-facial volumetric correction from SCULPTRA treatment, using three-dimensional digital surface imaging.

    Time frame: 6 months

Secondary outcomes

  1. Determine the mean change from baseline in Nasolabial volume as measured by 3-D digital surface imaging

    Time frame: 6 months

  2. Correlate volumetric correction with clinical improvement as measured by the Dermik Nasolabial Photo-numeric Scale.

    Time frame: 6 months

  3. Correlate the mean volumetric change in mid-facial treatment area with the amount of product used.

    Time frame: 6 months

  4. Determine mean change from baseline in the contour deficiency score as determined by the investigator.

    Time frame: 6 months

  5. Investigator Global Assessment of Improvement - Excellent Improvement

    Time frame: 6 months

  6. Investigator Global Assessment of Improvement - Much Improved

    Time frame: 6 Months

  7. Investigator Global Assessment of Improvement - Improved

    Time frame: 6 Months

  8. Investigator Global Assessment of Improvement - No Change

    Time frame: 6 Months

  9. Investigator Global Assessment of Improvement - Worse

    Time frame: 6 Months

  10. Subject Global Assessment of Improvement - Excellent Improvement

    Time frame: 6 Months

  11. Subject Global Assessment of Improvement - Much Improved

    Time frame: 6 Months

  12. Subject Global Assessment of Improvement - Improved

    Time frame: 6 Months

  13. Subject Global Assessment of Improvement - No Change

    Time frame: 6 Months

  14. Subject Global Assessment of Improvement - Worse

    Time frame: 6 Months

Sponsors and collaborators

Lead sponsor

Bausch Health Americas, Inc.

Industry

Registry information

Official study title

A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of Sculptra (Poly-L-lactic Acid) Measured by Three Dimensional Digital Surface Imaging

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Jun 18, 2007
Registry last updated
Sep 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.